Clinical Trial AI for Translational Research

Clinical trial AI belongs in a life sciences handbook because discovery programs fail at the translation step as often as they fail at the molecular step. Model-guided trials still need prespecified protocols, audit trails, and regulatory clarity.

Learning Objectives

• Distinguish trial operations AI from inferential AI.
• Identify where AI affects validity, not only efficiency.
• Use regulatory context when AI affects drug evidence.

TL;DR

AI in trials is safest when the context of use is explicit. Recruitment support, site selection, endpoint extraction, enrichment, and synthetic controls carry different evidentiary and regulatory burdens.

Introduction

FDA and EMA have both published materials addressing AI and machine learning across medicinal product development (FDA, 2026; EMA, 2024). The translation lesson is simple: an AI tool used to generate evidence for a product must be governed as part of the evidence-generation system.

Demonstrated

Demonstrated capability includes operational analytics, eligibility matching, real-world data curation, endpoint extraction, and risk-based monitoring support. FDA reports experience with submissions containing AI components from 2016 to 2023 in drug-development contexts (FDA, 2026). EMA’s adopted reflection paper covers AI across the medicinal product lifecycle (EMA, 2024).

Evidence Anchor	What It Supports	Practical Constraint
FDA drug AI page	Agency experience and guidance activity	Specific context of use determines evidence expectations
EMA reflection paper	Lifecycle framing for AI in medicines	Applicants remain responsible for validity and compliance
Bridge2AI	AI-ready biomedical data requirements	Trial data quality and provenance remain central

Theoretical

Theoretical capability includes adaptive trial systems that continuously update enrichment and operational strategy while preserving valid inference. That design requires prespecification, simulation, monitoring, and regulator engagement.

Beyond Current Capabilities

Beyond current capabilities includes replacing randomized evidence with model outputs for most therapeutic claims. Models support evidence generation. They do not remove the need for credible causal inference.

Practice Notes

• Write the AI context of use before selecting metrics.
• Separate operational endpoints from efficacy endpoints.
• Prespecify model updates, monitoring, and audit logs.
• Use regulator-facing documentation when model output affects trial evidence.